Table 5. Identified risk factors for asthma exacerbation: COREA cohort database.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | P value | No. of patients | OR | P value | No. of patients | |
| Age | 1.01 | 0.147 | 1,832 | |||
| Sex (female)* | 1.76 | < 0.001 | 1,832 | 1.87 | 0.006 | 995 |
| BMI | 0.99 | 0.986 | 1,802 | |||
| Pack-years | 0.99 | 0.435 | 1,627 | |||
| Pre-bronchodilator FEV1 (%) | 0.99 | 0.001 | 1,726 | 0.98 | 0.002 | 995 |
| Pre-bronchodilator FVC (%) | 0.99 | 0.016 | 1,726 | |||
| Pre-bronchodilator FEV1/FVC | 0.14 | < 0.001 | 1,727 | 0.111 | 0.039 | 995 |
| Post-bronchodilator FEV1 (%) | 0.99 | 0.012 | 1,023 | |||
| Post-bronchodilator FVC (%) | 0.99 | 0.108 | 986 | |||
| Post-bronchodilator FEV1/FVC | 0.26 | 0.043 | 1,022 | |||
| PC20 | 0.98 | 0.492 | 772 | |||
| Blood eosinophil (%) | 0.97 | 0.135 | 1,524 | |||
| Blood eosinophil (count) | 0.99 | 0.411 | 1,523 | |||
| Sputum eosinophil (%) | 0.99 | 0.399 | 333 | |||
| Sputum neutrophil (%) | 1.00 | 0.950 | 336 | |||
| Blood total IgE (IU/mL) | 0.99 | 0.134 | 786 | |||
| Log (total IgE) | 0.76 | 0.111 | 786 | |||
| CRP (mg/dL) | 0.98 | 0.854 | 794 | |||
| Allergic rhinitis | 0.74 | 0.137 | 1,029 | |||
| Aspirin hypersensitivity | 0.45 | 0.272 | 66 | |||
| Duration of asthma (month) | 1.00 | 0.051 | 1,657 | |||
| Symptom duration (month) | 1.00 | 0.380 | 1,803 | |||
| Duration of treatment (month) | 1.00 | 0.003 | 1,581 | 1.01 | 0.014 | 995 |
| Age at disease onset | 1.00 | 0.807 | 1,657 | |||
| History of asthma exacerbation | 1.83 | 0.001 | 1,809 | 1.46 | 0.055 | 995 |
| Mean of ΔFEV1 over 1 year (%) | 1.07 | < 0.001 | 933 | 1.06 | 0.002 | 796 |
| Mean of ΔFEV1 over 3 years (%) | 1.09 | 0.016 | 470 | 1.04 | 0.289 | 451 |
| Mean of ΔACT over 1 year (score) | 1.31 | < 0.001 | 857 | 1.27 | < 0.001 | 796 |
| Mean of ΔACT over 3 years (score) | 1.55 | < 0.001 | 468 | 1.50 | < 0.001 | 451 |
| Average ICS dose over 1 year (µg/day) | 1.00 | 0.227 | 1,381 | |||
| Average ICS dose over 3 years (µg/day) | 1.00 | 0.284 | 1,447 | |||
COREA, Cohort for Reality and Evolution of Adult Asthma in Korea; OR, odds ratio; BMI, body mass index; FEV1, forced expiration volume in 1 second; FVC, forced vital capacity; PC20, concentration of methacholine that caused a 20% fall in FEV1; IgE, immunoglobulin E; CRP, C-reactive protein; ACT, Asthma Control Test; ICS, inhaled corticosteroid. ΔFEV1: the absolute values for the changes in the FEV1 (which were measured over 3-months intervals). ΔACT: the absolute values for the changes in the ACT (which were measured over 3-months intervals).
*The sex defines female as related to male.